AstraZeneca stock falls as Etcamah trial setback clouds oncology outlook
Published on 09/12/2026 at 14:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca PLC stock (ISIN US6549022043) is under pressure after the company disclosed on September 11, 2026 that its Etcamah breast cancer pill failed to meet the primary endpoint in the pivotal SERENA-4 Phase III trial, denting expectations for one of its key oncology assets while the shares hover near USD 160 in New York.
Etcamah trial miss turns spotlight on oncology pipeline
According to GuruFocus on September 11, 2026, AstraZeneca announced that the SERENA-4 Phase III clinical trial evaluating Etcamah (camizestrant) in combination with palbociclib did not meet its primary endpoint of extending progression-free survival versus standard hormone therapy plus palbociclib in first-line treatment of ER-positive, HER2-negative advanced breast cancer.
As Economic Times Pharma reported on September 12, 2026, the company said the Etcamah combination delivered only a numerical, but not statistically significant, improvement in progression-free survival compared with standard therapy, limiting the case for broad first-line use even though side effects were in line with expectations.
In a similar vein, STAT News noted on September 12, 2026 that AstraZeneca confirmed the breast cancer pill failed in the pivotal trial as a first-line therapy in advanced tumors, with the Etcamah combination not outperforming standard treatment on the key measure of time until disease progression.
Fundamentals and valuation provide counterweight
Despite the oncology setback, AstraZeneca enters this period with solid recent financials. In its second-quarter 2026 report, the company generated total revenue of USD 15.38 billion, representing a 6.4 percent increase compared with the same quarter a year earlier, according to Yahoo Finance.
The same second-quarter 2026 update cited adjusted earnings per share of USD 2.63, which Yahoo Finance highlighted as being above analyst consensus estimates, underlining the group’s ability to translate mid-single-digit revenue growth into faster profit expansion.
Valuation metrics also frame the share move. On September 11, 2026, GuruFocus calculated a GF Value estimate of USD 182.10 for AstraZeneca versus a then-current New York price of USD 160.17, implying that the shares were roughly 12.0 percent undervalued on that framework.
Analyst expectations and upcoming earnings date
Market attention is already shifting toward the next set of numbers. According to a summary of MarketBeat and Zacks data dated September 11, 2026, consensus analyst targets compiled by MarketBeat point to an average price objective of USD 206.67 for AstraZeneca’s New York-listed shares, compared with a recent closing price of USD 159.71 on September 10, 2026, suggesting potential upside of about 29.4 percent if those expectations are met.
The same overview notes that, per Zacks data on September 9, 2026, AstraZeneca is expected to report its next quarterly earnings on November 5, 2026, with a consensus earnings-per-share estimate of USD 2.17 for the quarter ending in September 2026, which Zacks indicates would represent a year-over-year decrease of 8.82 percent compared with the same quarter a year earlier.
In addition, the Zacks-based commentary highlights that certain models forecast AstraZeneca could miss that upcoming quarterly consensus EPS by about 9.91 percent, underscoring that the earnings bar is relatively demanding at a time when trial risk in the pipeline has just materialized in breast cancer.
Risk factors from trials, pricing and regulation
Beyond Etcamah, investors are weighing a broader set of risks. Yahoo Finance points out that AstraZeneca has recently faced a setback in its rare disease division, where the antibody anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, even though encouraging results were seen in a subgroup.
The same analysis notes that datopotamab deruxtecan, co-developed with Daiichi Sankyo, delivered mixed Phase III TROPION-Lung01 results, with overall survival failing to reach statistical significance in the broader lung cancer population, which has cooled some peak sales expectations for that agent.
On the pricing front, Yahoo Finance highlights that AstraZeneca’s blockbuster heart and kidney drug Farxiga has been subjected to mandatory Medicare price reductions of 68 percent under the Inflation Reduction Act starting in 2026, a change that can compress United States margins even as global volumes hold up.
Regulatory and geopolitical factors also play a role. The same report mentions ongoing regulatory investigations in China involving senior executives and insurance compliance, adding operational uncertainty in one of AstraZeneca’s important growth markets.
Stock performance and reference price
On the New York Stock Exchange, AstraZeneca’s American Depositary Shares (ticker AZN) recently closed at USD 159.71 on September 10, 2026, up USD 2.77 or 1.76 percent on the day, according to data cited in a recent market summary.
The same New York-focused data set refers to a dividend yield around 2.72 percent as of September 10, 2026, based on US market information, giving income-oriented investors an additional metric to weigh alongside growth and trial risk.
Key data on AstraZeneca stock
- Company: AstraZeneca PLC
- ISIN: US6549022043
- Ticker: AZN
- Trading venue: New York Stock Exchange
- Price (as of September 10, 2026): 159.71 USD
- Market capitalization: 247,690,000,000 USD (as of September 10, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: November 5, 2026
